🇺🇸 FDA

Company profile · Sponsor

Lakefront

Lakefront Biotherapeutics NV

LKFT · NYSE pharma 2800 MECHELEN, USA
Pipeline
24
Drugs
0
Patents
0

Quick answer

Lakefront (LKFT) is a pharma company. headquartered in 2800 MECHELEN, USA. listed on NYSE. NovaPharmaNews links 24 pipeline programs, 0 drugs, and 0 patents to this profile..

Company facts

Ticker LKFT
Exchange NYSE
Company type pharma
Headquarters 2800 MECHELEN, USA
SEC CIK 0001421876

Pipeline (24)

Search pipeline →

  1. Filgotinib

    Lakefront

    Crohn's Disease

    phase 3 small molecule terminated

    2 trials

  2. Filgotinib

    Lakefront

    Ankylosing Spondylitis

    phase 3 small molecule terminated

    3 trials

  3. Filgotinib

    Lakefront

    Psoriatic Arthritis

    phase 3 small molecule terminated

    4 trials

  4. Filgotinib

    Lakefront

    Ulcerative Colitis

    phase 3 small molecule completed

    2 trials

  5. GLPG CAR T-cell therapy

    Lakefront

    Hematological Malignancies

    phase 3 gene therapy active

    1 trial

  6. GLPG1690

    Lakefront

    Idiopathic Pulmonary Fibrosis

    phase 3 small molecule terminated

    2 trials

  7. Filgotinib

    Lakefront

    Noninfectious Uveitis

    phase 2 small molecule terminated

    1 trial

  8. Filgotinib

    Lakefront

    Inflammatory Bowel Disease

    phase 2 small molecule terminated

    1 trial

  9. Filgotinib

    Lakefront

    Small Bowel Crohn's Disease

    phase 2 small molecule completed

    1 trial

  10. Filgotinib

    Lakefront

    Fistulizing Crohn's Disease

    phase 2 small molecule completed

    1 trial

  11. GLPG0259 oral capsule

    Lakefront

    Rheumatoid Arthritis

    phase 2 small molecule completed

    1 trial

  12. GLPG0634

    Lakefront

    Rheumatoid Arthritis

    phase 2 small molecule completed

    4 trials

  13. GLPG0634

    Lakefront

    Crohn's Disease

    phase 2 small molecule completed

    1 trial

  14. GLPG0974

    Lakefront

    Ulcerative Colitis

    phase 2 small molecule completed

    1 trial

  15. GLPG1205

    Lakefront

    Idiopathic Pulmonary Fibrosis

    phase 2 small molecule completed

    1 trial

  16. GLPG1205

    Lakefront

    Ulcerative Colitis

    phase 2 small molecule completed

    1 trial

  17. GLPG1690

    Lakefront

    Systemic Sclerosis

    phase 2 small molecule terminated

    2 trials

  18. GLPG1690 600 mg QD

    Lakefront

    Idiopathic Pulmonary Fibrosis

    phase 2 small molecule completed

    1 trial

  19. GLPG1837 dose 1

    Lakefront

    Cystic Fibrosis

    phase 2 small molecule completed

    2 trials

  20. GLPG1972

    Lakefront

    Osteoarthritis

    phase 2 small molecule completed

    1 trial

  21. GLPG2222 150 mg q.d.

    Lakefront

    Cystic Fibrosis

    phase 2 small molecule completed

    1 trial

  22. GLPG2222 50 mg

    Lakefront

    Cystic Fibrosis

    phase 2 small molecule completed

    1 trial

  23. GLPG2737

    Lakefront

    Autosomal Dominant Polycystic Kidney Disease

    phase 2 small molecule terminated

    1 trial

  24. GLPG2737

    Lakefront

    Cystic Fibrosis

    phase 2 small molecule completed

    1 trial

Frequently asked questions

What is Lakefront?

Lakefront (LKFT) is a pharma company. headquartered in 2800 MECHELEN, USA. listed on NYSE. NovaPharmaNews links 24 pipeline programs, 0 drugs, and 0 patents to this profile..

What pipeline programs does Lakefront sponsor?

We track 24 ClinicalTrials.gov-linked programs for Lakefront, including Filgotinib and 23 more. Open each program for phase, modality, NCT IDs, and indication details.

Where does Lakefront company data come from?

Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.